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a b s t r a c t
Simian-human immunodeﬁciency viruses (SHIVs) that mirror natural transmitted/founder (T/F) viruses
in man are needed for evaluation of HIV-1 vaccine candidates in nonhuman primates. Currently available
SHIVs contain HIV-1 env genes from chronically-infected individuals and do not reﬂect the character-
istics of biologically relevant HIV-1 strains that mediate human transmission. We chose to develop clade
C SHIVs, as clade C is the major infecting subtype of HIV-1 in the world. We constructed 10 clade C SHIVs
expressing Env proteins from T/F viruses. Three of these ten clade C SHIVs (SHIV KB9 C3, SHIV KB9 C4
and SHIV KB9 C5) replicated in naïve rhesus monkeys. These three SHIVs are mucosally transmissible
and are neutralized by sCD4 and several HIV-1 broadly neutralizing antibodies. However, like natural T/F
viruses, they exhibit low Env reactivity and a Tier 2 neutralization sensitivity. Of note, none of the clade C
T/F SHIVs elicited detectable autologous neutralizing antibodies in the infected monkeys, even though
antibodies that neutralized a heterologous Tier 1 HIV-1 were generated. Challenge with these three new
clade C SHIVs will provide biologically relevant tests for vaccine protection in rhesus macaques.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Chimeric simian-human immunodeﬁciency viruses (SHIVs)
were developed for studies of pathogenicity and preclinical assess-
ment of candidate HIV-1 vaccines in nonhuman primate (NHP)
models (Sato and Johnson, 2007). Chimeric viruses that contain
HIV-1 tat, rev, vpu and env genes, with the remainder of the virus
originating from the simian immunodeﬁciency virus (SIV), have
been used as challenge viruses to assess the ability of HIV-1
envelope glycoprotein (Env)-based vaccines to elicit antibodies that
prevent infection. However, currently available SHIV challenge
stocks have limitations. Many HIV-1 Envs do not produce viable
viruses when introduced into the SIV backbone. One of the ﬁrst
SHIVs to be generated that replicated robustly in rhesus monkeys
and caused an AIDS-like illness was SHIV-89.6P (Reimann et al.,
1996a, 1996b). However, this dual-tropic (CXCR4/CCR5-tropic) virus
exhibited in vivo preference for CXCR4, unlike the CCR5-tropism of
transmitted HIV-1 variants; thus, in infected monkeys, SHIV 89.6P
preferentially targeted naïve CD4þ T cells, a situation very different
from acute HIV-1 infection in humans (Igarashi et al., 2003;
Nishimura et al., 2004). SHIVs with exclusively CCR5-tropic envel-
opes have been generated; however viral loads and CD4þ T cell loss
in animals infected with these SHIVs have been variable (Pahar et
al., 2007; Pal et al., 2003; Parren et al., 2001; Tan et al., 1999).
The Envs of currently utilized SHIVs for which challenge stocks
are available, such as SHIV SF162P3 (Harouse et al., 1999) and SHIV
BaLP4 (Pal et al., 2003), were isolated from individuals chronically
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infected with HIV-1. As a result, these Envs were exposed to
extensive humoral and cellular immune pressure within the
infected individuals from whom they were isolated. Moreover, to
achieve consistency and higher replicative efﬁciency in vivo, these
SHIVs have been extensively passaged in monkeys. There is
evidence from HIV-infected humans and SIV-infected rhesus
monkeys that viral env genes accrue mutations during the course
of infection that allow them to escape from autologous neutraliz-
ing antibodies (Mikell et al., 2011; Moore et al., 2009; van Gils
et al., 2011; Yeh et al., 2010). It is thus likely that the neutralization
sensitivities of the chronic Envs used in current SHIVs are different
from those of the transmitted/founder (T/F) viruses that establish
infections in humans, and use of SHIVs that contain such chronic
Envs may bias the results of antibody protection studies in NHP.
A recent manuscript describes development of a new CCR5-tropic
SHIV expressing T/F Env from HIV-1 Clade B (Del Prete et al., 2014).
Both dual-tropic and CCR5-tropic SHIVs containing Envs from clade C
HIV-1 have previously been reported (Cayabyab et al., 2004; Chen et
al., 2000; Humbert et al., 2008; Ren et al., 2013; Siddappa et al., 2009;
Song et al., 2006). Some of these CCR5-tropic, clade C SHIVs encoded
env genes that were isolated from recently infected subjects
(Humbert et al., 2008; Ren et al., 2013). However, these SHIVs have
been passaged extensively in monkeys. Therefore, the envelopes
encoded in these SHIVs may have undergone sequence alterations
compared with the parental envelopes in the T/F viruses.
We hypothesized that SHIVs containing T/F HIV-1 env genes
would be able to better recapitulate the mucosal transmission
physiology of acute HIV infection, and thus more accurately reﬂect
the sensitivity of transmitted HIV-1 Envs to antibody-mediated
neutralization. Approximately 80% of individuals who are infected
via heterosexual contact are infected by one founder virus (Keele et
al., 2008). One of the early pathogenic SHIVs, KB9, began with the
introduction of tat, rev, vpu and env genes from a chronic clade B HIV-
189.6 into the SIVmac239 backbone. The resulting virus was passaged
in monkeys to produce the pathogenic SHIV 89.6P; SHIV KB9 is an
infectious, pathogenic molecular proviral clone derived from SHIV
89.6P-infected cells (Karlsson et al., 1997). Because KB9 was a viable
SHIV, we utilized the KB9 architecture to generate novel SHIVs with
the env genes of CCR5-tropic, Clade C T/F HIV-1 from acutely infected
individuals from South Africa. Three clade C SHIVs with T/F Envs that
are phylogenetically diverse infected rhesus macaques after atrau-
matic mucosal exposure. These three clade C SHIVs are the ﬁrst clade
C SHIVs that encode env genes isolated from T/F viruses at the earliest
stages of infection (Parrish et al., 2012). Clade C is the major infecting
subtype of HIV-1 infections globally. Our results provide insights into
the ability of Clade C T/F Envs to mediate mucosal transmission, to
generate neutralizing antibodies, and to establish persistent infections
in primates. Development of these three clade C SHIVs containing
phylogenetically diverse T/F env genes will greatly expedite
pre-clinical vaccine efﬁcacy studies as well as monoclonal antibody
passive infusion studies in the rhesus monkey model.
Results
In vivo selection of clade C T/F env expressing SHIVs
Ten different T/F HIV clade C env clones C1 through C10 were
isolated from acutely infected subjects sampled during Fiebig stages
I/II of infection (Fiebig et al., 2003) as part of a large cohort. These
envelopes were shown to be CCR5-tropic (Parrish et al., 2012). The
phylogenetic relationships of these 10 env genes are shown in Fig. 1.
As described in the Materials and Methods section, seven of these 10
clade C T/F env genes (C1 through C7) when cloned into the SHIV KB9
backbone generated replication-competent SHIVs. Infectious virus
was generated in vitro through transfection of 293T cells, followed by
expansion in human PBMCs. Two Mamu-An01-, Bn08-, Bn17-, naïve
Indian-origin rhesus monkeys were selected for this study. All seven
clade C T/F SHIVs (SHIV KB9 C1 through SHIV KB9 C7) were pooled in
equal ratios at 100 TCID50 for each virus and the virus mixture was
intravenously inoculated into two animals, which were followed for
the development of plasma viremia. Both the animals developed
viremia of 1106 RNA copies/ml by 2 weeks post-inoculation
(Fig. 2). One of the monkeys (A8V032) controlled SHIV replication,
with viremia dropping to undetectable levels by 49 days following
inoculation. The other monkey (A8V056) maintained a persistent
viremia of 1105 RNA copies/ml up to 130 days post-infection. From
the pool of seven T/F SHIVs that were inoculated in these two
monkeys, only SHIV KB9 C3, SHIV KB9 C4 and SHIV KB9 C5 were
identiﬁed in the plasma of monkey A8V056 at day 14. A total of 19
clones were isolated from the plasma of monkey A8V056 on day 14
post-infection; 4 of the 19 clones matched the sequence of SHIV KB9
C3, 14 clones matched the sequence of SHIV KB9 C4 and 1 clone
matched the sequence of SHIV KB9 C5. All seven clones isolated from
the plasma of monkey A8V056 on day 49 post-infection corre-
sponded to SHIV KB9 C3. SHIV KB9 C3 (2 of 10 clones) and SHIV
KB9 C5 (8 of 10 clones) were also detected in that same animal at day
98 post-infection. The sequences of all ﬁve clones isolated from
monkey A8V032 at day 14 post-infection matched those of SHIV KB9
C4. Sequencing of the isolated clones of SHIV KB9 C3, SHIV KB9 C4
and SHIV KB9 C5 viruses conﬁrmed that no nucleotide changes had
occurred by day 98 of infection, compared with the parental clones.
SHIV KB9 C3, SHIV KB9 C4, and SHIV KB9 C5 infection of rhesus
monkeys
To conﬁrm the infectivity and persistence of viremia of the
three clade C viruses isolated from the pool of seven SHIVs,
infectious molecular clones of these three SHIVs were transfected
into 293T cells to generate viruses. Previous observations in our
laboratory have shown that both SIV as well as SHIVs replicate to
higher titers in human PBMC compared to rhesus monkey PBMCs.
Therefore, we generated infectious stocks of all three clade C SHIVs
by culturing them in human PBMCs for 7–14 days, and then
harvesting supernatants for infection of rhesus monkeys. All three
challenge stocks were sequenced again. There was no change in
nucleotide sequences for SHIV KB9 C4 and SHIV KB9 C5. In SHIV
KB9 C3 there was an A-C change in position 2524.
A total of six Mamu-An01-, Bn08-, Bn17-, Trim5α-heterozygous
permissive Indian-origin rhesus macaques were inoculated intrave-
nously with 1000 TCID50 of either SHIV KB9 C3, SHIV KB9 C4 or SHIV
KB9 C5 (n¼2 per virus). All six animals became infected with a peak
viremia of at least 106 RNA copies/ml by 17–21 days after inoculation
(Fig. 3A). Both monkeys inoculated with SHIV KB9 C3 maintained a
persistent viremia of 103 RNA copies/ml up to 497 days post-
infection. Monkeys inoculated with SHIV KB9 C4 maintained a
persistent viremia of 103 RNA copies/ml up to 190 days post-
infection. One of the monkeys, 42-12, controlled infection around
day 300 with undetectable viremia. Both monkeys inoculated with
SHIV KB9 C5 maintained a persistent viremia of 103 RNA copies/ml
up to 190 days post-infection. Monkey 50-12 still has persistent
viremia of almost 104 RNA copies/ml at 497 days post-infection. No
signiﬁcant decline in total peripheral CD4þ T lymphocyte numbers
was detectable in these animals (Fig. 3B). Also no decline in memory
CD4þ T lymphocytes was observed in these animals (Fig S1).
Mucosal transmissibility of SHIV KB9 C3, SHIV KB9 C4, and SHIV KB9
C5 challenge stocks
Challenge stocks of the three clade C SHIVs were generated as
described in the Materials and Methods section. Viral RNA content of
the all three stocks and the TCID50 as measured on TZM-bl cells are
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described in Table 1. Sequence analyses of the viruses in the
challenge stocks showed no change in nucleotide sequences from
the parental viruses. We also conﬁrmed that these three viruses are
CCR5-tropic and not dual- or CXCR4-tropic (data not shown). Next
we sought to determine the mucosal transmissibility of the challenge
stocks of the three clade C SHIVs (Table 1). Undiluted stocks of SHIV
KB9 C3 (267,185 TCID50) and SHIV KB9 C5 (18,275 TCID50) were
inoculated into one naïve rhesus monkey each by the intrarectal
route. An undiluted stock of SHIV KB9 C4 (53,437 TCID50) was
inoculated intrarectally into two naïve rhesus monkeys. As shown
in Fig. 4A, challenge stocks of both SHIV KB9 C3 and SHIV KB9 C5
were able to establish infection in the monkeys when infected by the
mucosal route. Monkey 264-12, infected with SHIV KB9 C3, had a
peak viremia of 108 RNA copies/ml at 14 days post-infection and
persistent viremia of 103 RNA copies/ml up to 130 days. Monkey 266-
12, infected with SHIV KB9 C5, had a peak viremia of 107 RNA copies/
ml. However, the peak was delayed until day 35 post-infection, but
Fig. 1. Phylogenetic relationships of clade C T/F Envs used for SHIV construction. A maximum likelihood tree is shown that depicts the position of nine subtype C T/F env
sequences (C2–C10; bold) in relation to each other and reference strains (made using PhyML version 3 with a TVMþ IþG model chosen using Modeltest version 2.1.4). A
tenth env sequence (C1-19912872) was identiﬁed as an A/C recombinant and is thus not included in the analysis. Reference sequences included subtype C [BR025 (accession
# U52953), ETH2220 (U46016), 98IN012 (AF286231), 04ZASK146 (AY772699), ZM246F (FJ496192), CH0131 (KC894107), CH0185 (KC156129), CH0067 (KC156125), CH0200
(KC149183), and CH0164 (KC894125)] and subtype B [HXB2 (K03455)] strains. C2-C7 env genes (indicated by arrows), along with C1-19912872 env (not shown), were cloned
into the SHIV KB9 proviral backbone; SHIVs containing C3, C4 and C5 env genes (stars) were able to initiate a productive infection in monkeys. Bootstrap support values
greater than 70% are shown at nodes in the tree. The scale bar represents 0.05 substitutions/site.
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Fig. 2. In vivo selection of clade C T/F SHIVs. Seven clade C T/F env genes, C1
through C7, were cloned into the SHIV KB9 backbone to generate seven different
clade C SHIVs. These seven clade C SHIVs were combined in equal ratios (100
TCID50 of each of the viruses) to make a pool of viruses and were inoculated in two
naïve rhesus monkeys intravenously. Infecting clones of SHIVs were isolated from
the monkeys at various timepoints during the course of infection as indicated by
the arrows. Clones isolated frommonkey A8V032 are shown in “Red” letterings and
the time point is indicated by “Red” arrow, whereas clones isolated from monkey
A8V056 are shown in “Black” letterings and timepoints are shown in “black”
arrows. The number of clones present in the total number of isolated clones at each
timepoint is noted in parentheses next to each of the clones. Among nineteen
clones isolated from monkey A8V056 at day 14 post-infection, four clones matched
with SHIV KB9 C3, fourteen matched with SHIV KB9 C4 and one matched with SHIV
KB9 C5 sequences. A total of seven clones of SHIV KB9 C3 were isolated from
monkey A8V056 at day 49 post-infection and, at day 98 post-infection, two SHIV
KB9 C3 and eight SHIV KB9 C5 clones were detected in ten isolated clones. All ﬁve
clones isolated from monkey A8V032 at day 14 post-infection matched the
sequence of SHIV KB9 C4.
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Fig. 3. In vivo infectivity of the individual clones of SHIVs. Culture supernatants
containing 1000 TCID50 of SHIV KB9 C3, SHIV KB9 C4 or SHIV KB9 C5 were used to
infect two naïve rhesus monkeys each by the intravenous route. (A) Plasma viral
RNA level in monkeys. The data associated with SHIV KB9 C3 are shown in red,
SHIV KB9 C4 in blue and SHIV KB9 C5 in green symbols and lines. All three viruses
were able to establish infection with high peak viremia of 106–7 RNA copies/ml,
with sustained viremia up to 400 days post-infection. (B) CD4þ T lymphocyte
subsets were determined by multi-channel ﬂow cytometry for CD3, CD4, CD8,
CD28, CD95, CCR5 and CCR7. Total CD4þ T lymphocyte counts were calculated by
multiplying the total lymphocyte count by the percentage of CD3þ CD4þ T cells.
CD4þ T lymphocyte counts were monitored for all six monkeys post-infection and
are shown using same color scheme as in (A). No signiﬁcant decline in CD4þ T
lymphocyte counts was seen.
Table 1
SHIV KB9 C3, SHIV KB9 C4 and SHIV KB9 C5 challenge stock.
Viral load of stock TCID50/ml
SHIV KB9 C3 2.38108 copies/ml 267,185
SHIV KB9 C4 2108 copies/ml 53,437
SHIV KB9 C5 2.12108 copies/ml 18,275
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the virus persisted longer than SHIV KB9 C3. At the last measurement
at day 329 post-infection, 103 RNA copies/ml of virus were detected
(Fig. 4A). The SHIV KB9 C4 challenge stock also infected two naïve
rhesus monkeys when administered by the intrarectal route. Both
monkeys had a peak viremia of 106–7 RNA copies/ml between 14 and
22 days post-infection and persistent viremia of 103 RNA copies/ml
up to 182 days post-infection (Fig. 4B). No signiﬁcant change in the
absolute number of peripheral total or memory CD4þ T lymphocytes
was seen in these monkeys (Fig. S2).
Neutralization phenotype of SHIV KB9 C3, SHIV KB9 C4, and
SHIV KB9 C5
Primate immunodeﬁciency viruses vary in sensitivity to neutra-
lization by antibodies, and have been classiﬁed into tiers accord-
ingly (Seaman et al., 2010). The neutralization tiers of the three
clade C T/F SHIVs were evaluated using TZM-bl cells with a panel of
monoclonal antibodies (Table 2). We assessed the neutralization
sensitivity of SHIV KB9 C3, SHIV KB9 C4, and SHIV KB9 C5 challenge
stock viruses in TZM.bl assays using a panel of broadly neutralizing
mAbs (BNAbs) targeting multiple known epitopes on HIV-1 Env.
While all three SHIV viruses could be neutralized using soluble
human CD4 protein, variable sensitivity to a panel of four BNAbs
targeting the CD4 binding site (CD4bs) was observed (Table 2). SHIV
KB9-C3 was moderately sensitive to three of the CD4bs mAbs (b12,
VRC01, 3BNC117), SHIV KB9-C5 was sensitive to one (VRC01), and
SHIV KB9 C4 was resistant to all CD4bs BNAbs tested. All SHIV
viruses were resistant to neutralization by BNAbs 4E10 and 2F5 that
target the MPER-region of gp41, but demonstrated sensitivity to the
more potent mAb 10E8. We used a series of 7 antibodies targeting
either V3-glycan (2G12, PGT121, PGT128) or V1/V2 (CH01, PG9,
PG16, PGT145) epitopes and observed moderately positive titers
against SHIV KB9 C4 and SHIV KB9 C5, whereas SHIV KB9 C3 was
resistant to all seven of these BNAbs.
In addition to using epitope-speciﬁc mAbs, we further assessed
the overall relative neutralization sensitivity of the three SHIVs
using a diverse set of puriﬁed Ig samples from HIV-1-infected
individuals. All viruses were resistant to neutralization by a pooled
polyclonal clade B HIVIG, but SHIV KB9 C3 and SHIV KB9 C5 were
sensitive to a pooled polyclonal clade C HIVIG (Table 2). Six
puriﬁed Ig samples from clade C HIV-1-infected individuals from
South Africa known to exhibit broad and potent neutralizing
activity against acute clade C isolates were also tested. All three
SHIVs demonstrated moderate sensitivity or were resistant to
neutralization by this panel of clade-matched Ig. IC50 titers of
these mAbs and Ig reagents against a panel of four acute/early
clade C tier 2 HIV-1 Env pseudoviruses are shown in Table 2 for
comparative reference. Finally, we investigated whether the six
rhesus monkeys infected with either SHIV KB9 C3, SHIV KB9 C4, or
SHIV KB9 C5 developed autologous or heterologous neutralizing
antibody responses against these isolates. Plasma samples from
eight timepoints spanning 1–12 months post-infection were
tested from each animal against all three strains of SHIV. Surpris-
ingly, no plasma neutralizing activity was detected for up to 1 year
post-infection, even against the autologous infecting strain (data
not shown). Plasma samples from all animals did exhibit potent
neutralizing activity against a sensitive clade C Tier1A HIV-1 Env
pseudovirus (MW965.26), indicating that the animals did develop
neutralizing antibodies following challenge. Together, these data
indicate that, in the TZM.bl neutralization assay, SHIV KB9 C3,
SHIV KB9 C4, and SHIV KB9 C5 exhibit a neutralization phenotype
that is on the more resistant side of the sensitivity spectrum for
primary HIV-1 isolates (Seaman et al., 2010).
Determination of 50% monkey infectious doses (MID50) of SHIV KB9
C3 and SHIV KB9 C5 challenge stocks
We also sought to determine the 50% monkey infectious doses
(MID50) for SHIV KB9 C3 and SHIV KB9 C5 challenge stocks, as
these two viruses were neutralized by several monoclonal anti-
bodies more efﬁciently than SHIV KB9 C4.
First 1:100 and 1:50 dilutions of the SHIV KB9 C3 stock were
inoculated into two naïve, Indian-origin rhesus monkeys each by
the intra-rectal route. At these dilutions, all four monkeys remained
uninfected (data not shown). Next, three monkeys were challenged
with a 1:10 dilution and two monkeys were challenged with a 1:5
dilution of the virus intra-rectally. Two of the three monkeys
(monkeys R553, R566) challenged with the 1:10 dilution of the
virus became infected at day 14 post-infection with a peak plasma
viremia of 107–8 log/ml, while monkey R552 remained uninfected
(Fig. 5A). Both monkeys (R294, R546) challenged with the 1:5
dilution of the stock became infected with a peak viremia of 106–
7 log/ml. Monkey R294 became infected as early as day 7 post-
infection, but exhibited a peak of viremia at day 14 (Fig. 5A). This
shows the consistency of in vivo infectivity of the SHIV KB9 C3
challenge stock by the intra-rectal route. At a 1:5 dilution, this virus
challenge stock is 100% infectious administered intra-rectally.
As the SHIV KB9 C5 challenge stock has a lower TCID50 than the
SHIV KB9 C3 stock, we challenged monkeys (n¼2/dilution) with
undiluted or with 1:10, 1:5, 1:2 dilutions of SHIV KB9 C5 intra-
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Fig. 4. Mucosal transmissibility of the SHIV KB9 C3, SHIV KB9 C4, and SHIV KB9 C5 challenge stocks. Undiluted stocks of SHIV KB9 C3 and SHIV KB9 C5 (A) SHIV KB9 C4
(B) were inoculated into naïve rhesus monkeys by the intrarectal route. Challenge stocks of all three clade C T/F SHIVs were able to establish infection in the monkeys by the
mucosal route. Infections resulted in high peak viremia of 106–8 RNA copies/ml at 14–22 days post-infection. Persistent viremia of 103 RNA copies/ml was observed in the
SHIV KB9 C3-infected monkey up to 130 days post-infection. For the SHIV KB9 C5-infected monkey, plasma viral RNA of 103 copies/ml was detected up to 330 days post-
infection. For the SHIV KB9 C4-infected monkeys, viremia of 103 RNA copies/ml was observed up to 180 days post-infection.
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rectally. As shown in Fig. 5B, both monkeys challenged with the 1:2
dilution of SHIV KB9 C5 became infected. Peak viremia in all four
monkeys (R923, R545, R284, R544) infected with either the 1:2
dilution or undiluted virus was observed at day 14 with 107 log
plasma viral RNA copies/ml. However, one of the two monkeys
challenged with either the 1:10 or 1:5 dilution of the virus remained
uninfected. The monkeys that became infected (R556 and R557) had a
lower peak plasma viremia of 106 log copies/ml that was also delayed
at day 21 post-infection (Fig. 5B). These data show that the SHIV KB9
C5 challenge stock can infect 100% of the monkeys consistently by the
intra-rectal route at a 1:2 dilution and 50% of the monkeys at a 1:5 or
1:10 dilution.
Discussion
Nonhuman primate studies are extremely important for deter-
mining the efﬁcacies of different vaccine vectors, immunogens,
adjuvants and vaccination strategies before proceeding towards
phase I clinical trials. Recent clinical trials in humans and preclinical
studies in rhesus monkeys have suggested that antibodies against
HIV-1 Env may have some protective effects (Florese et al., 2009;
Hessell et al., 2009; Hidajat et al., 2009; Letvin et al., 2011.; Rerks-
Ngarm et al., 2009). Furthermore, studies of mucosal transmission of
HIV-1 infection have suggested that most transmission events are
founded by a single or very limited number of viral variants
Table 2
Neutralization assessment of SHIV KB9 C3, SHIV KB9 C4, SHIV KB9 C5.
Reagent Description IC50 Titer in TZM.bl cells (μg/ml)a
Primary SHIV isolates Acute/early clade C tier 2 pseudoviruses
SHIV KB9 C3 SHIV KB9 C4 SHIV KB9 C5 Ce1172_H1 Ce0393_C3 CAP45.2.00.G3 ZM233M.PB6
sCD4 soluble huCD4 0.71 4.65 2.91 4.96 21.50 26.00 2.90
b12 mAb-CD4bs 11.2 425 450 450 450 0.70 450
VRC01 mAb-CD4bs 2.26 425 34.84 410 0.62 410 1.67
3BNC117 mAb-CD4bs 29.42 425 450 450 0.20 3.88 0.13
CH31 mAb-CD4bs 450 450 450 NT NT NT NT
4E10 mAb-MPER 450 425 450 0.32 2.40 2.60 1.20
2F5 mAb-MPER 450 425 450 450 450 450 450
10E8 mAb-MPER 5.74 7.93 5.27 0.72 1.18 1.82 0.44
2G12 mAb-V3 Glycan 450 425 450 450 450 0.70 450
PGT128 mAb-V3 Glycan 450 1.5 450 0.01 450 450 450
PGT121 mAb-V3 Glycan 450 0.178 450 0.01 450 1.63 3.69
CH01 mAb-V1/V2 450 450 450 NT NT NT NT
PG9 mAb-V1/V2 450 425 1.84 0.07 0.02 0.01 0.01
PG16 mAb-V1/V2 450 425 0.23 0.01 o0.01 o0.01 o0.01
PGT145 mAb-V1/V2 450 450 0.165 0.26 0.11 o0.01 0.03
PGT151 mAb-gp41 450 450 450 450 450 0.01 0.03
HIVIG-B Clade B HIVþ polyclonal Ig 42500 42500 42500 850 1800 270 462
HIVIG-C Clade C HIVþ polyclonal Ig 256 4625 440 61 85 12 94
SA-C2 S. Africa clade C HIVþ Ig 2485 2419 2420 280 967 51 364
SA-C8 S. Africa clade C HIVþ Ig 42500 599 42500 749 45 108 132
SA-C44 S. Africa clade C HIVþ Ig 42500 1801 42500 627 228 23 48
SA-C62 S. Africa clade C HIVþ Ig 1146 2168 42500 48 122 210 55
SA-C72 S. Africa clade C HIVþ Ig 1099 2223 42500 2183 256 67 399
SA-C74 S. Africa clade C HIVþ Ig 1349 904 42500 820 42 508 646
NT: Not tested.
a Positive neutralization titers indicated in bold.
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Fig. 5. Determination of 50% monkey infectious doses (MID50) of SHIV KB9 C3, and SHIV KB9 C5 challenge stocks. (A) Two different dilutions of SHIV KB9 C3 were inoculated
into a total of ﬁve naïve rhesus monkeys by the intra-rectal route. Monkeys inoculated with a 1:10 dilution of the virus are shown in “Red” lines and symbols and those with
a 1:5 dilution are shown in “Blue” lines and symbols. One of the three monkeys (monkey R552) receiving a 1:10 dilution of the virus remained uninfected. (B) Four different
dilutions of SHIV KB9 C5 were inoculated into a total of eight naïve rhesus monkeys by the intra-rectal route. Monkeys inoculated with the undiluted virus stock or with, 1:2,
1:5 and 1:10 dilutions of the virus are shown in “Green”, “Magenta”, “Blue” and “Black” lines and symbols, respectively. One of the monkeys receiving 1:5 (monkey R550) and
1:10 (monkey R924) dilutions of the virus remained uninfected.
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(Abrahams et al., 2009; Keele et al., 2008). These two ﬁndings
prompted us to undertake the development of a SHIV encoding a
transmitted/founder Env from Clade C HIV-1 isolates, which are
responsible for the majority of HIV-1 infections worldwide.
We produced 7 replication-competent SHIVs containing Envs
from Clade C T/F HIV-1. The Envs encoded in these viruses were
directly cloned from HIV-1-infected subjects at Fiebig stage I/II of
infection, and correspond to the phylogenetic root of the swarm of
early circulating viruses. The Envs in these SHIVs thus correspond
precisely to those of T/F HIV-1. Based on prior experience, we
assumed that many HIV-1 env genes, when inserted into an SIV
backbone, would not yield a pathogenic SHIV. Thus, we used a novel
approach to simultaneously generate and assess in vivo multiple
SHIVs with different HIV-1 Envs. To increase the efﬁciency with
which a pathogenic SHIV might be isolated, we pooled multiple
recombinant viruses and inoculated them as a pool of viruses into
rhesus monkeys. Our hypothesis that only a small minority of HIV-1
Envs would produce a viable SHIV was conﬁrmed, as only three
viable viruses could be isolated. Even a close phylogenetic relation-
ship between viruses in the inoculum did not guarantee persistence
in the monkeys. Our results establish that at least some Clade C T/F
HIV-1 Env exhibit the ability to utilize rhesus macaque receptors
efﬁciently. Recently, a SHIV expressing HIV-1 clade B T/F Env has
been developed and reported (Del Prete et al., 2014). Although the
same cloning and selection strategies that we describe in our study
were used in that recent report, for in vivo selection of an infectious
clone from a pool of SHIVs, the monkeys were depleted of their
CD8þ T lymphocytes by pre-treatment with anti-CD8 antibody
prior to inoculation with the pool of viruses. Depletion of CD8þ T
lymphocytes in vivomay enhance infection and thereby selection of
viruses. Because we did not manipulate the immune status of our
monkeys, our study provides a more direct evaluation of the ability
of a T/F SHIV to establish infections in macaques.
We conﬁrmed that three SHIVs containing diverse clade C T/F
Env can reliably establish infection in rhesus monkeys after intra-
venous or intrarectal inoculation. Viral loads in different animals
infected with these SHIVs show very consistent peaks and sustained
viremia for a period of at least 150 days. This course is comparable
to that observed after infectionwith SIVmac251. All three SHIVs that
established persistent infections in the monkeys exhibited low Env
reactivity, and were relatively resistant to soluble CD4 and neutra-
lizing antibodies (Tier 2 phenotype). Thus, low Env reactivity is
compatible with the establishment of persistent infections in vivo
(Haim et al., 2011). A lower level of inter-animal variability in post-
infection viral loads could potentially simplify the interpretation of
vaccination effects on post-transmission peak and set point viremia,
and increase the power to detect differences between vaccine
groups for given cohort sizes. The challenge stocks of these three
T/F viruses were prepared from acutely infected monkeys, mini-
mizing in vivo passaging that can cause changes in genetic and
biological properties of the viruses.
The low Env reactivity of T/F HIV-1 (Keele et al., 2008; Haim
et al., 2011) likely contributes to the ability of viruses to avoid the
host neutralizing antibody responses. Like most T/F HIV-1, the
three Clade C SHIVs are relatively resistant to antibody neutraliza-
tion. In the monkeys infected with these SHIVs, only very limited
levels and types of neutralizing antibodies were elicited. Remark-
ably, no autologous neutralizing antibodies were detected in any of
the Clade C T/F SHIV-infected monkeys for up to 1 year after
infection. However, antibodies capable of neutralizing a hetero-
logous Clade C HIV-1 with a highly reactive, Tier 1 Env were
elicited in these monkeys. This same pattern of antibody genera-
tion was observed in monkeys infected with a Clade B SHIV, and
shown to be related to the low Env reactivity, with respect to
soluble CD4 and cold, of the infecting virus (McGee et al., 2014).
Apparently, low Env reactivity not only inﬂuences virus sensitivity
to neutralizing antibodies (Haim et al., 2011), but also modulates
the structure of the Env antigens presented to the humoral
immune system during natural infection. Presumably, Env ele-
ments commonly targeted by strain-speciﬁc neutralizing antibo-
dies during early infection are less accessible and/or immunogenic
in the Clade C T/F Envs in the three successful SHIVs in this study.
However, these Clade C T/F Envs still present entry-relevant
conformations to the host immune system, allowing the genera-
tion of neutralizing antibodies with some breadth. Understanding
the structural basis of these immunogenic properties of Clade
C T/F Envs may guide the design of improved vaccine candidates.
Although signiﬁcant declines in peripheral blood CD4þ T lym-
phocytes have not occurred to date in the monkeys infected with
these SHIVs, it is premature to reach conclusions about the patho-
genicity of these viruses. It is not unusual for monkeys that are
persistently viremic with SHIV infections to succumb to AIDS-like
illness 3–4 years after inoculation, and the monkeys in this study
have been observed for only approximately 1.5 years. About 2/3 of
the monkeys infected with these Clade C T/F SHIVs exhibit persistent
viremia, so some of these monkeys may develop disease in time.
Development of these three viruses provides novel information
about the in vivo behavior of viruses with Envs from well-documented
T/F HIV-1 from Clade C. Clade C HIV-1 variants constitute the majority
of viruses infecting humans in the current pandemic. Therefore, the
behavior of Clade C T/F SHIVs in vivo is of great relevance to our
understanding of the majority of new HIV-1 transmissions occurring
in the world today. Thus, the availability of the clade C T/F SHIVs
enables studies of virus transmission and immunogenicity, and should
expedite the development of prophylactic approaches.
Materials and methods
Construction of clade C T/F SHIVs
We utilized env genes from 10 clade C T/F viruses from South
Africa (C1-19912872, C2-21197826, C3-21283649, C4-20927783,
C5-1245045, C6-20258279, C7-19157834, C8-20915593, C9-
20965238, and C10-21197826) to construct SHIVs. Some of these T/F
viruses (C3–C7) have already been reported (Parrish et al., 2012).
Clones C1, C2, C8, C9 and C10 were also isolated from clade C-infected
subjects at Fiebig stage I/II of infection (personal communication).
GenBank accession numbers for all 10 viruses are provided in Table S1
of the Supplementary materials. These 10 clade C T/F env genes were
cloned into the SHIV KB9 backbone. A Cla1 restriction site was
introduced immediately upstream of the env ATG and an Age1restric-
tion site upstream of the 30 gp41 HIV-SIV recombination junction of
SHIV KB9. Cla1 and Age 1 restriction sites were introduced into the T/F
env sequences as well to facilitate cloning of the T/F env in SHIV KB9.
As a result of this cloning strategy, exon 2 of tat, rev and 30 half of vpu
of SHIV KB9 were replaced by those of the new T/F virus. However,
exon 1 of tat, rev as well as the 50end of vpu, which lie outside env,
remained from SHIV KB9 (Fig. 6). However, only seven of the viruses
(C1 through C7) were replication competent, whereas, viruses con-
structed with env genes from C8, C9 and C10 were not.
Study animals
A PCR-based assay was used to select adult Indian-origin rhesus
monkeys that were Mamu-An01-ve, Bn08-ve, B*17-ve, and Trim5α
heterozygous permissive (Barouch et al., 2000; Letvin et al., 2011).
Monkeys were housed at the New England Primate Research
Center, Southborough, MA and at Bioqual, Inc, Rockville, MD. All
monkeys were maintained in accordance with the Guide for the
Care and Use of Laboratory Animals. All animal protocols were
approved by the Institutional Care and Use Committee.
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Viral isolation and sequencing
Viral RNA was extracted from monkey plasma using the QIAamp
Viral RNA Isolation Kit (Qiagen) and reverse transcribed using
SuperScript III (Invitrogen) with the primer rt1 (GATTG-
TATTTCTGTCCCTCAC), which recognizes a sequence immediately
downstream of the stop codon of the HIV env gene of SHIV KB9
(Genbank accession U89134). The viral genomic fragment from the
tat start codon to the env stop codon was ampliﬁed using Easy-A
High Fidelity (Agilent Technologies) with the primers p1 (CTAGAAG-
CATGCTGTAGAGCAAG) and p2 (GATTGTATTTCTGTCCCTCAC). The RT-
PCR product was sequenced by Genewiz, Inc. (South Plainﬁeld, NJ).
Generation of infectious virus and animal inoculation
Plasmids containing the infectious molecular clones were trans-
fected into 293T cells using Lipofectamine 2000 (Invitrogen). Cell
culture supernatants were collected after 48 h and clariﬁed through
a 0.4 μm ﬁlter. These supernatants were then used to infect CD8þ T
cell-depleted human peripheral blood mononuclear cells (PBMCs).
Brieﬂy, PBMCs were isolated from the whole blood of healthy
human donors by Ficoll-Hypaque centrifugation and stimulated
with 6.25 μg/mL concanavalin-A (Con-A) and 20 U/ml interleukin-2
(IL-2). The following day, PBMCs were depleted of CD8þ T cells
using the CD8þ T cell depletion kit (Stem Cell Technologies). 100 μL
of transfected 293T cell supernatant was applied to every 10 million
cells, and cells were incubated for between 7 and 10 days. Infected
PBMC supernatants were then harvested, clariﬁed of cellular debris
by 0.4 μm ﬁltration, and stored at 80 1C. Virus was quantiﬁed by
SIV p27 ELISA (Zeptometrix), and the 50% tissue culture infectious
dose (TCID50) was determined on TZM-bl cells. Mamu-An01-, Bn08-,
Bn17-, Trim5α heterozygous permissive animals were inoculated
intravenously with 1000 TCID50 virus.
Generation of challenge stocks of SHIV KB9 C3, SHIV KB9 C4, and SHIV
KB9 C5
Virus challenge stocks of the three clade C SHIVs with T/F Envs
were prepared by co-culturing naïve rhesus monkey PBMCwith PBMC
and lymph node cells from the infected monkeys. At the peak of
viremia, 20–30ml of blood and lymph node biopsies were taken from
the monkeys infected intravenously with SHIV KB9 C3, SHIV KB9 C4
and SHIV KB9 C5. PBMC and lymph node cells from each monkey
were enriched for CD4þ T lymphocytes by depleting CD8þ T
lymphocytes and were cultured separately in RPMI 1640 supplemen-
ted with 10% fetal bovine serum, 6.25 μg/ml Con-A and 20 U/ml IL-2.
Forty-eight hours later, the cells were washed and resuspended in
RPMI 1640 supplemented with 10% fetal bovine serum, and 20 U/ml
IL-2. PBMC from naïve rhesus monkeys that had been stimulated with
Con-A were mixed with the PBMC from the infected monkeys at a 1:1
ratio. Virus replication was monitored every other day by measuring
the p27 content of the culture supernatants. Supernatants were
harvested from days 14–21 of the cultures. The cell-free culture
supernatants were frozen in small aliquots to be used as virus
challenge stocks for nonhuman primate studies. The viral RNA content
and the infectivity of the stocks were determined for all three
challenge stocks (Table 1).
CD4þ T lymphocyte subset analyses
CD4þ T lymphocyte subsets were determined by multi-channel
ﬂow cytometry for CD3, CD4, CD8, CD28, CD95, CCR5 and CCR7. CD4þ
T lymphocyte counts were calculated by multiplying the total lym-
phocyte count by the percentage of CD3þ CD4þ T cells. Brieﬂy, 100 μl
of EDTA-anticoagulated whole blood was stained with anti-CD3-A700
(clone SP34.2), anti-CD4-PerCP Cy5.5 (clone L200), anti-CD8-APC
H7 (clone SK1), anti-CCR5-PE (clone 3A9), anti-CD95 APC (clone
DX2) all from BD Biosciences, anti-CD28-PE CY7 (clone CD28.2;
eBiosciences), and anti-CCR7-FITC (clone 150503; R&D Systems). Fixed
cells were collected (30,000 events) on a LSRII instrument using
FACSDiva software version 6.1.1 (BD Biosciences) and data were
analyzed usingFlowJo Software (TreeStar, Ashland, OR).
Plasma viral RNA measurement
Plasma viral RNA measurements were performed at CHAVI
Viral Core Laboratory, IVQAC, Duke Human Vaccine Institute,
Durham, NC. Plasma viral loads were assessed using a Qiagen
QIAsymphony DSP Virus/Pathogen Midi Kit using the QIAsymph-
ony SP platform and real-time PCR reaction carried out on the
StepOnePlus (Applied Biosystems) instrument. Data from the real-
time PCR reaction was analyzed using the StepOnePlus software.
The sensitivity of this SIV viral load assay has been shown to be
250 copies per ml.
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Fig. 6. Schematic diagram of T/F SHIVs constructs. T/F env genes were cloned into the SHIV KB9 backbone. A Cla1 restriction site was introduced immediately upstream of
the env ATG and an Age1 restriction site upstream of the 30 gp41 HIV-SIV recombination junction of SHIV KB9. Cla1 and Age 1 restriction sites were introduced into the T/F env
sequences as well to facilitate cloning of the T/F env in SHIV KB9. As a result of this cloning strategy, exon 2 of tat, rev and 30 half of vpu of SHIV KB9 were replaced by those of
the new T/F virus and exon 1 of tat, rev as well as the 50end of vpu, which lie outside env, remained from SHIV KB9. Genes from SHIV KB9 are shown in “Dotted” boxes and the
cloned genes are shown in “White” boxes.
M. Asmal et al. / Virology 475 (2015) 37–45 43
Neutralization assays
Neutralizing antibody titers against primary SHIV isolates were
measured using a luciferase-based assay in TZM.bl cells as pre-
viously described (Monteﬁori, 2005; Sarzotti-Kelsoe et al., 2013).
This assay measures the reduction in luciferase reporter gene
expression in TZM.bl cells following infection. Brieﬂy, 3-fold serial
dilutions of monoclonal antibody (mAb) reagents or plasma sam-
ples were performed in duplicate, and the 50% inhibitory concen-
tration (IC50) titer was calculated as the dilution that caused 50%
reduction in relative luminescence units (RLU) compared to virus
control wells after subtraction of cell control RLU. All data were
analyzed using 5-parameter curve ﬁtting. mAbs 4E10, 2G12, 2F5,
b12, PG9, PG16, and VRC01 were obtained commercially (Polymun
Scientiﬁc), as was soluble human CD4 protein (Progenics). 3BNC117
was kindly provided by Michel Nussenzweig (Rockefeller University,
New York, NY). PGT121, PGT128, PGT145, and PGT151 were gener-
ously provided by Dennis Burton (The Scripps Research Institute, La
Jolla, CA). Puriﬁed Ig were obtained from clade C HIVþ plasma
samples purchased from the South African National Blood Services
(Johannesburg) and provided by Dr. Lynn Morris.
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